Alzheon
Latest round
- —
Last raised
- Oct 2026
Total raised
- $196M
Investors
- 3
About Alzheon
, Alzheon, Inc. operates as a provider of small-molecule inhibitors for Alzheimer's disease to patients at high genetic risk, including those with the APOE4 gene. In June 2024, Alzheon, Inc. The company provides a wide range of biopharmaceutical products, such as valiltramiprosate (ALZ-801), a Phase 3 oral anti-amyloid treatment for Alzheimer's disease. Additionally, the firm also provides precision medicine approaches targeting neurodegenerative disorders, focusing on the inhibition of protein misfolding and aggregation.
Who invested in Alzheon
3 investors across 5 rounds
See all investors in Alzheon
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Alzheon
Who invested in Alzheon?
Alzheon has 3 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Alzheon raised?
Alzheon has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
What does Alzheon do?
Alzheon is a biotechnology company.
Where is Alzheon headquartered?
Alzheon is headquartered in Framingham, US.
Which VCs invest in companies like Alzheon?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Alzheon's stage. Their profiles are linked below.
VCs backing biotechnology startups
Raising like Alzheon? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.